Novo Nordisk’s diabetes numbers were encouraging although the biopharma business spoiled the party. Group sales grew by 3% in LC (5% in DKK) to DKK28.5bn – diabetes and obesity business grew by 11% in LC (+13% in DKK) but the hemophilia business declined by 25% in LC (-24% in DKK). Europe contributed the most (37% of the growth), as the US accounted for 34% of the growth, unlike Q4 which was largely driven by the other markets. China grew by 8% in LC (30% of the total growth) to D
04 May 2017
Strong diabetes and profitability...but don’t get swayed too early
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong diabetes and profitability...but don’t get swayed too early
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
04 May 2017 -
Author:
Kamla Singh -
Pages:
3
Novo Nordisk’s diabetes numbers were encouraging although the biopharma business spoiled the party. Group sales grew by 3% in LC (5% in DKK) to DKK28.5bn – diabetes and obesity business grew by 11% in LC (+13% in DKK) but the hemophilia business declined by 25% in LC (-24% in DKK). Europe contributed the most (37% of the growth), as the US accounted for 34% of the growth, unlike Q4 which was largely driven by the other markets. China grew by 8% in LC (30% of the total growth) to D